Literature DB >> 20127093

Biology of interleukin-22.

Kerstin Wolk1, Ellen Witte, Katrin Witte, Katarzyna Warszawska, Robert Sabat.   

Abstract

Interleukin (IL)-22 is a member of the IL-10 family of cytokines and represents an important effector molecule of activated Th22, Th1, and Th17 cells, as well as Tc-cell subsets, gammadelta T cells, natural killer (NK), and NKT cells. IL-22 mediates its effects via a heterodimeric transmembrane receptor complex consisting of IL-22R1 and IL-10R2 and subsequent Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling pathways including Jak1, Tyk2, and STAT3. Whereas in some aspects, IL-22 acts synergistically with tumor necrosis factor-alpha, IL-1beta, or IL-17, most functions of IL-22 are unique. Importantly, IL-22 does not serve the communication between immune cells. It mainly acts on epithelial cells and hepatocytes, where it favors the antimicrobial defense, regeneration, and protection against damage and induces acute phase reactants and some chemokines. This chapter illuminates in detail the properties of IL-22 with respect to its gene, protein structure, cellular sources, receptors, target cells, biological effects, and, finally, its role in chronic inflammatory diseases, tumors, and infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127093     DOI: 10.1007/s00281-009-0188-x

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  109 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Interleukin 20: discovery, receptor identification, and role in epidermal function.

Authors:  H Blumberg; D Conklin; W F Xu; A Grossmann; T Brender; S Carollo; M Eagan; D Foster; B A Haldeman; A Hammond; H Haugen; L Jelinek; J D Kelly; K Madden; M F Maurer; J Parrish-Novak; D Prunkard; S Sexson; C Sprecher; K Waggie; J West; T E Whitmore; L Yao; M K Kuechle; B A Dale; Y A Chandrasekher
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

3.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

4.  Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats.

Authors:  He Chang; Haruo Hanawa; Hui Liu; Tsuyoshi Yoshida; Manabu Hayashi; Ritsuo Watanabe; Satoru Abe; Ken Toba; Kaori Yoshida; Raafat Elnaggar; Shiro Minagawa; Yuji Okura; Kiminori Kato; Makoto Kodama; Hiroki Maruyama; Junichi Miyazaki; Yoshifusa Aizawa
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

Review 5.  The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.

Authors:  Sandra Philipp; Kerstin Wolk; Stephanie Kreutzer; Elizabeth Wallace; Nina Ludwig; Joachim Roewert; Conny Höflich; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  Expert Opin Ther Targets       Date:  2006-12       Impact factor: 6.902

Review 6.  Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity.

Authors:  Marco Colonna
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

7.  Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Authors:  Weici Zhang; Yongyan Chen; Haiming Wei; Chaogu Zheng; Rui Sun; Jian Zhang; Zhigang Tian
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 8.  Three decades of psoriasis research: where has it led us?

Authors:  Robert Sabat; Wolfram Sterry; Sandra Philipp; Kerstin Wolk
Journal:  Clin Dermatol       Date:  2007 Nov-Dec       Impact factor: 3.541

9.  Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis.

Authors:  Leandra Mfuna Endam; Yohan Bossé; Abdelali Filali-Mouhim; Chantale Cormier; Pierre Boisvert; Louis-Philippe Boulet; Thomas J Hudson; Martin Desrosiers
Journal:  Otolaryngol Head Neck Surg       Date:  2009-02-28       Impact factor: 3.497

10.  Comparison of interleukin-22 and interleukin-10 soluble receptor complexes.

Authors:  Naomi J Logsdon; Brandi C Jones; Kristopher Josephson; Jennifer Cook; Mark R Walter
Journal:  J Interferon Cytokine Res       Date:  2002-11       Impact factor: 2.607

View more
  171 in total

1.  Interleukin-22: implications for liver ischemia-reperfusion injury.

Authors:  Paul J Chestovich; Yoichiro Uchida; William Chang; Mark Ajalat; Charles Lassman; Robert Sabat; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

2.  Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages.

Authors:  Christophe Paget; Stoyan Ivanov; Josette Fontaine; Joelle Renneson; Fany Blanc; Muriel Pichavant; Laure Dumoutier; Bernhard Ryffel; Jean Christophe Renauld; Philippe Gosset; Pierre Gosset; Mustapha Si-Tahar; Christelle Faveeuw; François Trottein
Journal:  J Biol Chem       Date:  2012-01-31       Impact factor: 5.157

3.  Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

Authors:  LeShara M Fulton; Michael J Carlson; James M Coghill; Laura E Ott; Michelle L West; Angela Panoskaltsis-Mortari; Dan R Littman; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

4.  Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.

Authors:  Melissa G Works; Fangfang Yin; Catherine C Yin; Ying Yiu; Kenneth Shew; Thanh-Thuy Tran; Nahoko Dunlap; Jennifer Lam; Tim Mitchell; John Reader; Paul L Stein; Annalisa D'Andrea
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

5.  Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia.

Authors:  Jiang Cao; Chong Chen; Li Li; Zeng Ling-yu; Li Zhen-yu; Yan Zhi-ling; Chen Wei; Cheng Hai; Wei Sang; Xu Kai-lin
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

Review 6.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

Review 7.  A Molecular Link Between Interleukin 22 and Intestinal Mucosal Wound Healing.

Authors:  Xiaoyan Sun; Laura Chalmers; Xiaobing Fu; Min Zhao
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-12       Impact factor: 4.730

8.  Interleukin 22 inhibits intracellular growth of Mycobacterium tuberculosis by enhancing calgranulin A expression.

Authors:  Rohan Dhiman; Sambasivan Venkatasubramanian; Padmaja Paidipally; Peter F Barnes; Amy Tvinnereim; Ramakrishna Vankayalapati
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

Review 9.  Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

Authors:  Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

Review 10.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.